Randomized Trialhigh evidence
Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial.
JAMA·October 8, 2026·PMID 42848371
Why it mattersNicotinamide riboside is widely used as an over-the-counter NAD+ precursor with purported neuroprotective benefits, but this rigorous trial shows no benefit and possible harm in early Parkinson disease. Clinicians should counsel patients that this supplement is not effective for motor or nonmotor symptoms and may worsen disease progression.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled